Comparative Pharmacology
Head-to-head clinical analysis: LEVEMIR FLEXTOUCH versus TOUJEO MAX SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVEMIR FLEXTOUCH versus TOUJEO MAX SOLOSTAR.
LEVEMIR FLEXTOUCH vs TOUJEO MAX SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that activates insulin receptors, promoting glucose uptake and inhibiting gluconeogenesis.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action. It binds to the insulin receptor, activating downstream signaling pathways to promote glucose uptake in peripheral tissues, inhibit hepatic gluconeogenesis, and suppress lipolysis and proteolysis.
Subcutaneous injection, once or twice daily; starting dose 0.2-0.3 units/kg/day, titrate to target glycemic control.
Subcutaneous injection once daily at the same time every day. Starting dose for patients with type 2 diabetes: 0.2 units/kg or 10 units once daily, titrated based on fasting plasma glucose. Maximum dose per injection: 160 units (2 mL) or 300 units (3 mL) depending on prefilled pen.
None Documented
None Documented
Terminal half-life: approximately 5-7 hours (subcutaneous injection). The prolonged half-life relative to regular human insulin is due to reversible albumin binding, providing a flat, prolonged pharmacokinetic profile. Clinically, this supports once- or twice-daily dosing.
Terminal elimination half-life of 19 hours (range 16-21 h) in steady state, reflecting prolonged insulin glargine absorption from the subcutaneous depot.
Renal: approximately 50-70% of administered dose undergoes renal clearance as intact insulin; fecal: negligible (<10%). Insulin detemir is extensively metabolized in the liver (via dipeptidyl peptidase IV and other proteolytic enzymes) and the kidney, with metabolites excreted in urine.
Degraded by insulin-degrading enzyme; minimal renal excretion (<1% unchanged). Biliary/fecal elimination accounts for the remainder.
Category C
Category C
Long-Acting Insulin
Long-Acting Insulin